Dupilumab De-escalation in Pediatric Atopic Dermatitis
Recruiting
Phase 4
Interventional Study
Atopic Dermatitis
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
At a Glance
- Age
- 1 – 17
- Sex
- Any
- Trial phase
- Phase 4
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 30 (estimated)
- Sponsor
- Johns Hopkins University · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
This is a pilot investigator-blinded, randomized clinical trial to assess the feasibility of dupilumab treatment discontinuation or dose-reduction in children aged 1-17 years who have achieved sustained atopic dermatitis (AD) control on dupilumab.
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Aged 1 to \<18 years old, either sex, any race or ethnicity
* Provide signed informed consent by parent or legal guardian and informed assent if applicable
* Has a physician confirmed diagnosis of atopic dermatitis
* Has received dupilumab for at least 12 months for the treatm…
Contacts